India, April 21 -- Following the global initiative to raise awareness about Acute Myeloid Leukemia (AML), a rare and aggressive form of blood cancer, AbbVie has announced its entry into the Indian oncology market with the introduction of Venetoclax for the treatment of both Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL).

This significant milestone reflects AbbVie's dedication to addressing unmet medical needs and improving patient outcomes in India's ongoing fight against cancer.

Acute Myeloid Leukemia (AML) is a rapidly progressing hematological malignancy that affects blood and bone marrow, characterised by limited treatment options and low survival rates.

Venetoclax, a first-in-class BCL-2 inhibitor, offers a no...